

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Zylox-Tonbridge Medical Technology Co., Ltd.**

**歸創通橋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2190)**

### **VOLUNTARY ANNOUNCEMENT NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED MARKETING APPROVAL FOR ZYLOX UNICORN® SUTURE-MEDIATED CLOSURE SYSTEM**

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”, together with its subsidiary, the “**Group**” or “**we**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development of the Group.

The Company is pleased to announce that ZYLOX Unicorn® Suture-mediated Closure System, self-developed by the Group, has recently been granted marketing approval by the National Medical Products Administration (the “**NMPA**”). As the first self-developed suture-mediated closure system product in the country, the grant of marketing approval for ZYLOX Unicorn® Suture-mediated Closure System marks the breakthrough of the monopoly of imported brands in the market of vascular puncture site suture solutions by domestic brands. The launch of ZYLOX Unicorn® Suture-mediated Closure System will be conducive to the widespread use of domestic substitution suture-mediated closure technique, reducing patients’ braking time, lowering the risk of puncture complications, and enabling more patients to be entitled to high quality and affordable innovative medical technology. As of the date of this announcement, the Company has obtained approvals from the NMPA for a total of 44 products in the People’s Republic of China and CE marking in the European Union for eight products, covering Germany, Italy, Argentina, Brazil, the United Arab Emirates and other countries in Europe, South America and the Middle East.

The suture-mediated closure system is a widely used medical device designed for fast, accurate and effective closure of vascular incisions or puncture sites during procedures. Particularly in vascular surgery and interventional procedures, the suture-mediated closure system can be used for angioplasty, bypass surgery, aneurysm resection, and post-puncture closure of vessels, effectively simplifying and accelerating the process of vascular closure, reducing the surgical time, while improving the safety and success rate of procedures, and decreasing the risk of post-operative complications.

The innovation and development of vascular interventional medical devices have led to a gradual increase in the clinical demand for large bore suture-mediated closure systems. Compared with the vascular closure system, ZYLOX Unicorn<sup>®</sup> Suture-mediated Closure System has an expanded suture range of 5F–22F, which is compatible with large bore sutures of 8F or above, and is expected to realize more application scenarios in clinical use and meet unmet clinical needs. The successful grant of approval for ZYLOX Unicorn<sup>®</sup> Suture-mediated Closure System is not only a demonstration of the Company's innovation and research and development strength, but also another important milestone with respect to the Company's active response to clinical needs and the promotion of enhancement in independent innovation capability of the industry.

By order of the board  
**Zylox-Tonbridge Medical Technology Co., Ltd.**  
**Dr. Jonathon Zhong Zhao**  
*Chairman and Executive Director*

Hong Kong, June 3, 2024

*As of the date of this announcement, the board of directors comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive directors.*